Moderna Expands Horizons With Vertex and Chiesi Deals
Pacts Come Ahead Of R&D Day
The world is waiting for Moderna’s COVID-19 vaccine results, but meanwhile the company is exploring new avenues to secure long-term growth
You may also be interested in...
In addition to its near-monopoly in cystic fibrosis, the US biotech behemoth is continuing its deal-making in other areas and has become the latest company to link up with Skyhawk.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
After a long-standing row with payer NHS England, the rapid market access deal will help Vertex move into growth phase.